Medigus Ltd. (NASDAQ:MDGS) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 126,200 shares, an increase of 123.8% from the September 15th total of 56,400 shares. Based on an average daily volume of 2,950,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.6% of the company’s shares are sold short.
NASDAQ:MDGS traded up $0.02 on Thursday, reaching $1.43. 342 shares of the stock traded hands, compared to its average volume of 2,200,697. The company’s 50 day moving average is $1.49 and its 200-day moving average is $1.69. Medigus has a 1-year low of $1.35 and a 1-year high of $4.19.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDGS. Goldman Sachs Group Inc. bought a new position in shares of Medigus during the 2nd quarter valued at approximately $52,000. Jane Street Group LLC purchased a new stake in Medigus during the first quarter valued at approximately $127,000. Citadel Advisors LLC acquired a new position in Medigus during the 1st quarter valued at approximately $216,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Medigus in the second quarter worth $452,000.
Medigus Ltd. engages in research and development of medical treatment for the gastrointestinal tract. Its product is the MUSE system, an endoscopic device to perform Transoral Fundoplication for the treatment of gastroesophageal reflux disease. The company was founded by Elazar Sonnenschein on December 9, 1999 and is headquartered in Omer, Israel.
Featured Story: Technical Analysis
Receive News & Ratings for Medigus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigus and related companies with MarketBeat.com's FREE daily email newsletter.